Type IIType II DiabetesDiabetes & EndocrinologyFamily PracticeNursingOBGYN & Women's HealthPsychiatryInternal MedicinePathologyDiabetesType 2 DiabetesDisabilitiesMental IllnessPrescription DrugsGeneral HealthScreening
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, Nov. 11, 2015 (HealthDay News) -- About 30 percent of adults with severe mental illness (SMI) taking antipsychotic medications undergo diabetes-specific screening using validated screening measures, according to a study published online Nov. 9 in JAMA Internal Medicine.
Christina Mangurian, M.D., from the University of California in San Francisco, and colleagues conducted a retrospective cohort study to examine diabetes screening among 50,915 publicly insured adults with SMI taking antipsychotic medications. The authors also examined characteristics predictive of screening. Data were examined during two study periods: Jan. 1, 2009, to Dec. 31, 2009, and Oct. 1, 2010, to Sept. 30, 2011.
The researchers found that 30.1 percent of the cohort received diabetes-specific screening. In a yearlong period, 31.1 percent received no form of glucose screening. Having at least one outpatient primary care visit during the period examined was the strongest correlate of diabetes-specific screening (adjusted prevalence ratio, 1.8; P < 0.001).
"Growing evidence supports the value of screening for diabetes mellitus in higher-risk populations, such as those receiving treatment with antipsychotic medications, including first-generation and second-generation agents that commonly result in co-occurring obesity," the authors write. "Future studies should explore barriers to screening in this vulnerable population."
One author disclosed financial ties to the pharmaceutical industry.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 31, 2022
Read this Next
Other Trending Articles